Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants.
Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V, D'Oro U, Finco O, Garçon N, El Idrissi M, Janssens M, Leroux-Roels G, Marchant A, Schwarz T, Van Damme P, Volpini G, van der Most R, Didierlaurent AM, Burny W. Budroni S, et al. Among authors: bourguignon p. NPJ Vaccines. 2021 May 21;6(1):78. doi: 10.1038/s41541-021-00337-0. NPJ Vaccines. 2021. PMID: 34021167 Free PMC article.
Noncanonical DNA polymerization by aminoadenine-based siphoviruses.
Pezo V, Jaziri F, Bourguignon PY, Louis D, Jacobs-Sera D, Rozenski J, Pochet S, Herdewijn P, Hatfull GF, Kaminski PA, Marliere P. Pezo V, et al. Among authors: bourguignon py. Science. 2021 Apr 30;372(6541):520-524. doi: 10.1126/science.abe6542. Science. 2021. PMID: 33926956
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD, Sow SO, Mbaye KD, Thiongane A, Ndiaye BP, Ndour CT, Mboup S, Keshinro B, Kinge TN, Vernet G, Bigna JJ, Oguche S, Koram KA, Asante KP, Gobert P, Hogrefe WR, De Ryck I, Debois M, Bourguignon P, Jongert E, Ballou WR, Koutsoukos M, Roman F; Zaire EBola Research Alliance group. Tapia MD, et al. Among authors: bourguignon p. Lancet Infect Dis. 2020 Jun;20(6):719-730. doi: 10.1016/S1473-3099(20)30019-0. Epub 2020 Mar 19. Lancet Infect Dis. 2020. PMID: 32199492 Clinical Trial.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Tapia MD, Sow SO, Ndiaye BP, Mbaye KD, Thiongane A, Ndour CT, Mboup S, Ake JA, Keshinro B, Akintunde GA, Kinge TN, Vernet G, Bigna JJ, Oguche S, Koram KA, Asante KP, Hogrefe WR, Günther S, Naficy A, De Ryck I, Debois M, Bourguignon P, Jongert E, Ballou WR, Koutsoukos M, Roman F; Zaire EBola Research Alliance group. Tapia MD, et al. Among authors: bourguignon p. Lancet Infect Dis. 2020 Jun;20(6):707-718. doi: 10.1016/S1473-3099(20)30016-5. Epub 2020 Mar 19. Lancet Infect Dis. 2020. PMID: 32199491 Clinical Trial.
Erratum: Author Correction: Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Van Deun K, Smilde AK, van den Berg RA, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, van der Most R, Didierlaurent AM. Coccia M, et al. Among authors: bourguignon p. NPJ Vaccines. 2018 Mar 21;3:13. doi: 10.1038/s41541-018-0047-7. eCollection 2018. NPJ Vaccines. 2018. PMID: 29582861 Free PMC article.
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Deun KV, Smilde AK, Berg RAVD, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, Most RV, Didierlaurent AM. Coccia M, et al. Among authors: bourguignon p. NPJ Vaccines. 2017 Sep 8;2:25. doi: 10.1038/s41541-017-0027-3. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263880 Free PMC article.
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.
Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F. Dinges W, et al. Among authors: bourguignon p. Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673. Medicine (Baltimore). 2016. PMID: 26871794 Free PMC article. Clinical Trial.
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB. Huang Y, et al. Among authors: bourguignon p. Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29. Curr Opin Virol. 2016. PMID: 26827165 Free PMC article. Review.
33 results